Recent developments highlight clinical progress with ersodetug, regulatory interactions with the FDA, and financial liquidity updates.

• Rezolute outlined clinical milestones for ersodetug and reported $108 million in cash and short-term investments combined as of late 2026 [N1].
• The company completed enrollment in the Phase 3 upLIFT study for tumor hyperinsulinism [N2].
• FDA recommended a pre-BLA meeting as a next regulatory step for ersodetug in congenital HI [N3].
• Rezolute is preparing for a potential BLA filing for ersodetug in congenital HI [N4].
• The company posted a narrower loss in Q4 and expects topline data from the Phase 3 ersodetug study by the end of 2026 [N5].
• Market activity showed a 38% stock jump in early June 2026 amid positive clinical updates [N8].

The bull case for Rezolute centers on the potential of ersodetug to address a significant unmet need in treating refractory hypoglycemia across various forms of hyperinsulinism. Positive clinical data from the sunRIZE and upLIFT studies, along with FDA Breakthrough Therapy Designation and a recommended pre-BLA meeting, support the therapeutic promise. Strong liquidity provides runway for continued development and regulatory activities. If regulatory authorities accept the totality of evidence, ersodetug could become a novel treatment option for patients with congenital and tumor-associated HI.

The bear case involves the failure of clinical trials to meet primary endpoints, as seen in the sunRIZE study, and the FDA potentially requiring additional studies or data before approval. Regulatory uncertainties and the possibility of delays or increased costs could impact the company's operational plans and financial resources. Adverse events or safety concerns in clinical trials could halt development. The niche rare disease market and competitive landscape also pose commercialization challenges. Financial losses and the need for ongoing funding add to execution risks.

Rezolute's moat is primarily based on its focus on rare diseases with high unmet medical need, specifically refractory hypoglycemia associated with hyperinsulinism. Its lead asset, ersodetug, targets a unique allosteric site on the insulin receptor, potentially offering a novel mechanism of action applicable across multiple forms of HI. The company's clinical progress and Breakthrough Therapy Designation status provide regulatory engagement advantages. However, the moat is contingent on successful clinical development and regulatory approval, with inherent risks in late-stage biopharmaceutical development and competition in rare disease therapeutics.

• Regulatory Approval Uncertainty: FDA may require additional clinical studies or data beyond current submissions, potentially delaying approval and increasing costs.
• Clinical Trial Execution Risks: Delays, modifications, or failures in clinical trials could impact development timelines and outcomes.
• Safety and Adverse Events: Unexpected adverse events in trials could halt development or lead to regulatory restrictions.
• Financial and Operational Risks: Ongoing losses and potential need for additional funding could affect operational plans and liquidity.

• Rezolute, Inc. is a late-stage rare disease company focused on developing therapies for refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI).
• The lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody targeting the insulin receptor to down modulate insulin receptor activity and restore glucose levels.
• Ersodetug is being developed to treat any form of HI, both genetic and acquired, acting downstream from the cause of disease.
• The sunRIZE Phase 3 study for congenital HI did not meet its primary or key secondary endpoints but showed clinically relevant and nominally statistically significant improvements in multiple continuous glucose monitoring (CGM) endpoints.
• FDA met with Rezolute on March 17, 2026, under Breakthrough Therapy Designation to discuss sunRIZE results and recommended submission of comprehensive datasets for independent evaluation.
• FDA recommended a pre-Biologics License Application (BLA) meeting as a precursor to a BLA submission for ersodetug in congenital HI, but did not opine on approvability or sufficiency of data.
• Rezolute completed enrollment in the Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism and expects topline results by end of 2026.
• The company reported $8.15 million in cash and cash equivalents and $81.85 million in short-term investments as of September 30, 2026, with a current ratio of 9.92 and cash ratio of 9.51, indicating strong liquidity.
• Rezolute posted a net loss of $18.49 million and basic and diluted EPS of -$0.18 for the quarter ended September 30, 2026.
• Risks include potential FDA requirements for additional clinical studies, uncertainty about regulatory approval timelines, and the possibility that clinical trials may not replicate earlier positive results.
• Interim and topline clinical data may change as more data become available and are subject to audit and verification.
• Delays or changes in clinical trial design, enrollment, or regulatory requirements could increase costs and delay commercialization.
• Adverse events in clinical trials could interrupt or halt development and regulatory approval.
• Rezolute's operating plans and cash resources could be impacted by FDA decisions regarding the sufficiency of clinical data and regulatory pathways.